International Generic Drug Prices: How U.S. Costs Compare Globally

When you walk into a pharmacy in the U.S. and see a $6 bottle of generic lisinopril, it’s easy to think you’re getting a bargain. But here’s the twist: you are getting a bargain-compared to almost every other developed country. At the same time, if you’re paying $500 for a brand-name drug like Jardiance, you’re paying nearly four times what someone in Japan or Australia pays for the same pill. The U.S. doesn’t have high drug prices across the board. It has two drug markets: one where generics are dirt cheap, and one where brand-name drugs are the most expensive in the world.

Generic Drugs in the U.S. Are Cheaper Than Almost Everywhere Else

Here’s a fact most people don’t know: 90% of all prescriptions filled in the U.S. are for generic drugs. And those generics? They cost, on average, 33% less than the same drugs in countries like Canada, Germany, or the U.K. According to a 2022 study by the RAND Corporation, the U.S. pays just 67 cents for every dollar spent on generics elsewhere. That’s not a fluke. It’s the result of a market built on fierce competition.

When a brand-name drug loses its patent, dozens of companies rush to make copies. The FDA approves them quickly. Once three or four manufacturers enter the market, prices drop to 15-20% of the original brand price. That’s not theory-it’s data. IQVIA’s sales reports show that when five companies sell the same generic, prices often fall below $5 for a 30-day supply. In many cases, you can buy generic metformin for $4 at Walmart. In the U.K., the same amount costs $12. In France, it’s $15.

Why does this happen? Volume. The U.S. buys more generic drugs than any other country. That gives pharmacies and insurers massive negotiating power. Medicare Part D, which covers millions of seniors, buys generics in bulk and demands deep discounts. Even private insurers use their size to squeeze prices down. The result? A system that works-when it’s not broken by monopolies.

Brand-Name Drugs? The U.S. Is the Most Expensive Market on Earth

But flip the script, and everything changes. For brand-name drugs-those still under patent-the U.S. is the outlier. The same RAND study found U.S. list prices for originator drugs are 422% higher than in other OECD countries. That means if a drug costs $100 in Japan, you’ll pay $422 in the U.S. before insurance.

Take Jardiance, a diabetes drug. In Australia, it costs about $52 per month. In Japan, it’s $48. In the U.S., Medicare negotiated a price of $204. That’s not a discount-it’s still nearly four times the global average. Stelara, used for psoriasis and Crohn’s disease, costs $2,822 in the U.K. In the U.S., Medicare pays $4,490. Even after negotiations, the U.S. still pays more.

Why? Because the U.S. doesn’t negotiate prices the way other countries do. In Canada, Germany, and France, the government sets a maximum price based on what it thinks the drug is worth. In the U.S., drugmakers set the price-and then insurers, PBMs, and Medicare try to claw it back with rebates. That’s why list prices look insane, but net prices (after rebates) are lower.

The Rebate Trap: Why List Prices Lie

Here’s where things get confusing. You see a drug listed at $1,000 on a pharmacy’s website. But you pay $50. Why? Because the manufacturer gave a rebate to your insurer. That rebate doesn’t go to you-it goes to the middlemen. The system is designed so that insurers and pharmacy benefit managers (PBMs) get paid based on how much they negotiate down the list price. The higher the list price, the bigger the rebate-and the bigger the cut for the middleman.

That’s why drugmakers raise list prices every year, even when the actual cost to make the drug hasn’t changed. It’s not about profit-it’s about the rebate game. A 2024 University of Chicago study found that when you look at net prices after rebates, the U.S. actually pays 18% less than countries like Canada and Germany for the same drugs. But here’s the catch: those rebates don’t help patients who pay out-of-pocket. If you don’t have insurance, you pay the full list price. And that’s where the U.S. becomes unaffordable.

Why Some Generics Suddenly Become Expensive

It’s not always cheap. Sometimes, a generic drug that’s been on the market for years suddenly spikes in price. Why? Because the competition disappeared.

When a generic drug has only one or two makers, prices stay low. But if one company goes bankrupt, gets bought out, or decides to quit making the drug, the market can collapse. That’s what happened with doxycycline, a common antibiotic. In 2013, dozens of companies made it. By 2018, only two were left. Prices jumped from $20 for a 30-day supply to $1,800. The FDA documented over 200 cases of generic drug shortages since 2010, many caused by manufacturers leaving the market because profits were too thin.

It’s a cruel irony: the system that keeps generics cheap also makes it risky for manufacturers to stay in. If the price drops too low, they lose money. So they exit. Then the few remaining companies raise prices. The FDA calls this “market failure.” Patients call it price gouging.

Medicare’s Negotiations: A Step Forward, But Not Enough

In 2022, Congress gave Medicare the power to negotiate prices for 10 high-cost drugs. The first round of negotiations lowered prices for drugs like Jardiance and Eliquis-but not enough. Medicare’s negotiated price for Jardiance is still 3.9 times higher than the average price in 11 other countries. For Stelara, it’s 1.6 times higher. And these are the drugs Medicare picked because they were the most expensive.

So what’s the point? It’s a start. But the real savings come from generics. The FDA estimates that the 773 generic drugs approved in 2023 will save the U.S. system $13.5 billion in a single year. That’s more than all the Medicare negotiations combined. Accelerating generic approvals is the most powerful tool we have to bring down drug costs.

What This Means for You

If you’re on a generic drug, you’re winning. You’re paying less than people in most other countries. Keep using mail-order pharmacies, shop around with GoodRx, and ask your doctor if there’s a generic alternative. Most of the time, there is.

If you’re on a brand-name drug, you’re paying the price for a broken system. Ask your doctor about biosimilars-these are cheaper versions of biologic drugs that work just like the original. Check if your drug is on Medicare’s negotiation list. If it’s not, call your insurer and demand they negotiate. And if you’re paying cash, always ask for the cash price. Sometimes it’s lower than your insurance copay.

The U.S. doesn’t have a drug pricing problem. It has two. One is solved: generics are cheap because competition works. The other is still broken: brand-name drugs are priced like luxury goods because no one’s forcing the makers to lower them. Until that changes, Americans will keep paying more for the same pills-and the rest of the world will keep paying less.

How to Save on Medications Right Now

• Use GoodRx or SingleCare: These apps show you the lowest cash price at pharmacies near you, often lower than insurance copays.
• Ask for a 90-day supply: Many generics cost less per pill when bought in bulk.
• Check for manufacturer coupons: Even brand-name drugs often have discount cards that cut the price in half.
• Switch to generic: If your doctor prescribes a brand-name drug, ask: “Is there a generic version?” In 90% of cases, there is.
• Use mail-order pharmacies: For chronic meds, mail-order often cuts costs by 30-50%.

What’s Next for Drug Pricing?

The next round of Medicare-negotiated drugs is due by February 1, 2026. That could mean 15-20 more drugs get price caps. But the real game-changer will be if the U.S. starts pushing for international price alignment-either by linking Medicare prices to global averages or by forcing drugmakers to offer the same price overseas as they do here.

Some experts argue that U.S. high prices fund global innovation. Others say it’s unfair to make Americans pay for the world’s R&D while other nations free-ride. The truth? The system is unsustainable. Either the U.S. will force down brand-name prices, or other countries will stop buying U.S.-made drugs. Either way, change is coming.

For now, know this: if you’re on a generic, you’re getting one of the best deals in global healthcare. If you’re on a brand, you’re paying the cost of a system that hasn’t caught up with reality. The fix isn’t complicated-it’s competition. More generics. More transparency. Less rebate games. And for the first time, a government willing to say: no more.